{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:51:21Z","timestamp":1768535481661,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ymgme.2016.11.390","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T21:03:31Z","timestamp":1480712611000},"page":"22-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["The metabolism of glucocerebrosides \u2014 From 1965 to the present"],"prefix":"10.1016","volume":"120","author":[{"given":"Anthony H.","family":"Futerman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances M.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2016.11.390_bb0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.1138375","article-title":"Exploring cells with a centrifuge","volume":"189","author":"De Duve","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2016.11.390_bb0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0021-9258(18)97611-8","article-title":"The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue","volume":"240","author":"Brady","year":"1965","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0006-291X(65)90743-6","article-title":"Metabolism of glucocerebrosides II: evidence of an enzymatic deficiency in Gaucher's disease","volume":"18","author":"Brady","year":"1965","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0020","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1172\/JCI105417","article-title":"Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease","volume":"45","author":"Brady","year":"1965","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.0.CO;2-S","article-title":"Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease","volume":"15","author":"Stone","year":"2000","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.tips.2004.01.004","article-title":"New directions in the treatment of Gaucher disease","volume":"25","author":"Futerman","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0035","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/sj.embor.embor873","article-title":"X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease","volume":"4","author":"Dvir","year":"2003","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0040","series-title":"Gaucher Disease","year":"2006"},{"key":"10.1016\/j.ymgme.2016.11.390_bb0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ymgme.2009.01.006","article-title":"Participation of asparagine 370 and glutamine 235 in the catalysis by acid beta-glucosidase: the enzyme deficient in Gaucher disease","volume":"97","author":"Liou","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0050","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1074\/jbc.M511110200","article-title":"Analyses of variant acid beta-Glucosidases: effects of Gaucher disease mutations","volume":"281","author":"Liou","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0055","doi-asserted-by":"crossref","first-page":"29052","DOI":"10.1074\/jbc.M705005200","article-title":"Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease","volume":"282","author":"Brumshtein","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0060","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1074\/jbc.M110.150433","article-title":"X-ray and biochemical analysis of N370S mutant human acid-glucosidase","volume":"286","author":"Wei","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0065","doi-asserted-by":"crossref","first-page":"42105","DOI":"10.1074\/jbc.M110.172098","article-title":"Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S","volume":"285","author":"Offman","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0070","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/protein\/gzr032","article-title":"Comparison of a molecular dynamics model with the X-ray structure of the N370S acid-beta-glucosidase mutant that causes Gaucher disease","volume":"24","author":"Offman","year":"2011","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0075","article-title":"Emerging therapeutic targets for Gaucher disease","volume":"000\u2013000","author":"Vitner","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ymgme.2016.11.390_bb0080","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","article-title":"LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of \u03b2-glucocerebrosidase","volume":"131","author":"Reczek","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ymgme.2016.11.390_bb0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","article-title":"Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages","volume":"20","author":"Brumshtein","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2016.11.390_bb0090","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","article-title":"Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2016.11.390_bb0095","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","article-title":"Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system","volume":"5","author":"Shaaltiel","year":"2007","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0100","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature13476","article-title":"Sphingolipid lysosomal storage disorders","volume":"510","author":"Platt","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2016.11.390_bb0105","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1016\/S0021-9258(18)91935-6","article-title":"Enzymatic synthesis of ceramide-glucose and ceramide-lactose by glycosyltransferases from embryonic chicken brain","volume":"243","author":"Basu","year":"1968","journal-title":"J. Biol. Chem."},{"issue":"Pt 2","key":"10.1016\/j.ymgme.2016.11.390_bb0110","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1042\/bj2800295","article-title":"Determination of the intracellular sites and topology of glucosylceramide synthesis in rat liver","volume":"280","author":"Futerman","year":"1991","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0115","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0076-6879(81)72057-3","article-title":"Inhibitors of cerebroside metabolism","volume":"72","author":"Radin","year":"1981","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00731489","article-title":"Treatment of Gaucher disease with an enzyme inhibitor","volume":"13","author":"Radin","year":"1996","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0125","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0022-2275(20)39895-3","article-title":"Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth","volume":"36","author":"Abe","year":"1995","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0130","doi-asserted-by":"crossref","first-page":"19365","DOI":"10.1074\/jbc.272.31.19365","article-title":"Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin","volume":"272","author":"Platt","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0135","first-page":"472","article-title":"Miglustat. Oxford GlycoSciences\/Actelion","volume":"4","author":"Lachmann","year":"2003","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ymgme.2016.11.390_bb0140","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1016\/S0021-9258(17)37202-2","article-title":"N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis","volume":"269","author":"Platt","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0145","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M113.463562","article-title":"Beta-glucosidase 2 (GBA2) activity and imino sugar pharmacology","author":"Ridley","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0150","first-page":"139","article-title":"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200\u2013500CD4 cells\/mm3","volume":"7","author":"Fischl","year":"1994","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0155","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2016.11.390_bb0160","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/mp200313e","article-title":"Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase","volume":"8","author":"Abian","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0165","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0006-2952(99)00384-6","article-title":"N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo","volume":"59","author":"Andersson","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0170","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.intimp.2004.04.008","article-title":"Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis","volume":"4","author":"Shen","year":"2004","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0175","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","article-title":"ELIGLUSTAT TARTRATE: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease","volume":"35","author":"Shayman","year":"2010","journal-title":"Drugs Future"},{"key":"10.1016\/j.ymgme.2016.11.390_bb0180","article-title":"ArticlesEliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"1\u20138","author":"P.T.M.C. F MedSci, G.D. MD, R.C. MD, M.B. MD, T.A.B. MD, A.M.M. MD","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2016.11.390_bb0185","series-title":"Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe","author":"Belmatoug","year":"2016"},{"key":"10.1016\/j.ymgme.2016.11.390_bb0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","article-title":"Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients","volume":"11","author":"Smid","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0195","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ymgme.2009.12.006","article-title":"Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial","volume":"99","author":"Wraith","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.11.390_bb0200","series-title":"Celastrol Increases Glucocerebrosidase Activity in Gaucher Disease by Modulating Molecular Chaperones","first-page":"1","year":"2013"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216303559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216303559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T02:49:35Z","timestamp":1657939775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719216303559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":40,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1096719216303559"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.11.390","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The metabolism of glucocerebrosides \u2014 From 1965 to the present","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.11.390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}